Brief: Shanghai Henlius Biotech Says Biologics License Application For Biosimilar Of Denosumab Hlx14 Accepted By Us FDA
30/10/2024 10:29
Oct 30 (Reuters) - Shanghai Henlius Biotech 2696.HK :
* BIOLOGICS LICENSE APPLICATION FOR BIOSIMILAR OF DENOSUMAB
HLX14
ACCEPTED BY US FDA
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln